New York Cancer & Blood Specialists Opens State-of-the-Art Cancer Center on Manhattan's Upper East Side
New York, NY June 18, 2025 --( PR.com )-- New York Cancer & Blood Specialists (NYCBS), one of the nation's leading oncology practices, proudly announces the opening of its newest state-of-the-art cancer treatment center located at 210 East 86th Street, 6th Floor, New York, NY 10028. Located in Yorkville, this new Manhattan center reaffirms the practice's commitment to delivering high-quality, community-based cancer care across New York City.
The new center offers a full spectrum of cancer care services under one roof. The facility was designed with patients in mind, featuring a warm, healing environment and a host of amenities that promote comfort, dignity, and wellness throughout the treatment journey.
'This new center is a true testament to our mission of delivering comprehensive cancer care that's not only accessible, but also compassionate,' said Dr. Jeff Vacirca, CEO of NYCBS. 'We're proud to expand our footprint in Manhattan and continue bringing world-class care closer to where our patients live and work.'
The Upper East Side location is staffed by a distinguished team of board-certified oncologists and hematologists, including Dr. Steven Gruenstein, Dr. Amory Novoselac, Dr. Brenda Panzera, Dr. Niculae Ciobanu, Dr. Visaharan Sivasubramaniam, and Dr. Tong Dai. Together, they bring decades of experience, clinical excellence, and a compassionate approach to each patient they treat.
In addition to cutting-edge medical oncology and hematology services, the center offers access to supportive care, clinical trials, infusion therapy, advanced diagnostics, and patient-centered programs, all within a modern, patient-first environment.
To make an appointment, call 212-861-6660. For more information, visit nycancer.com.
Read More
Contact Information:
New York Cancer & Blood Specialists
Mike Scanlon, Marketing Director
631-574-8366
Contact via Email
Read the full story here: New York Cancer & Blood Specialists Opens State-of-the-Art Cancer Center on Manhattan's Upper East Side
Press Release Distributed by PR.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
5 hours ago
- Medscape
Datroway Gains Second FDA Nod With NSCLC Approval
The FDA has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo) for certain patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Specifically, the Trop-2-directed antibody and topoisomerase inhibitor conjugate was approved for adults previously treated with an EGFR-directed therapy and platinum-based chemotherapy, according to the approval notice. The approval marks the second for the antibody drug conjugate, which was discovered by Daiichi Sankyo and is being jointly developed with AstraZeneca. Initial approval was granted in January for previously treated patients with unresectable or metastatic HR-positive, HER2-negative breast cancer, as reported by Medscape. The new approval was based on efficacy demonstrated in a pooled subgroup of 114 patients treated with datopotamab deruxtecan in the TROPION-Lung05 and TROPION-Lung01 trials. The confirmed overall response rate among the patients was 45%, and the median duration of response was 6.5 months. Patients in the two trials were treated at the recommended dose of 6 mg/kg, up to a maximum of 540 mg for patients weighing 90 kg or more, given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity. Last year, AstraZeneca voluntarily withdrew its marketing authorization application with the EU's medicines regulator for the antibody drug conjugate for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer based on the TROPION-Lung01 phase 3 trial. The decision 'was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency,' the drug company said in a press release. Reuters previously reported that data from TROPION-Lung01 'has repeatedly knocked [AstraZeneca's] shares, most recently in September when results showed that the drug did not significantly improve overall survival results for patients.' Full prescribing information for datopotamab deruxtecan, which will be posted on Drugs@FDA, includes warnings and precautions for interstitial lung disease/pneumonitis, ocular adverse reactions, stomatitis, and embryo-fetal toxicity. Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape, MDedge, and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics. She can be reached at sworcester@ or on X: @SW_MedReporter.
Wall Street Journal
6 hours ago
- Wall Street Journal
Why Can't New York Fix Hospice Care First?
My colleagues in Albany say they voted for 'medical aid in dying,' but that's a euphemism. Your editorial 'New York's Assisted-Suicide Mistake' (June 11) gets to the heart of the issue—that the state Senate granted the government and medical professionals the power to sanction death. I voted no on the bill for several reasons. Among them: I believe all life is precious and that no one can predict the future with certainty. We shouldn't make irreversible decisions based on imperfect 'terminal' prognoses. The state also shouldn't speak out both sides of its mouth. New York spends millions each year on improving mental-health and antisuicide efforts. The bill would send a contradictory and dangerous message.
CNET
6 hours ago
- CNET
Today's NYT Strands Hints, Answer and Help for June 24 #478- CNET
Looking for the most recent Strands answer? Click here for our daily Strands hints, as well as our daily answers and hints for The New York Times Mini Crossword, Wordle, Connections and Connections: Sports Edition puzzles. Today's NYT Strands puzzle is a tough one. Some of the answers are really long, and untangling them could take you awhile. If you need hints and answers, read on. I go into depth about the rules for Strands in this story. If you're looking for today's Wordle, Connections and Mini Crossword answers, you can visit CNET's NYT puzzle hints page. Read more: NYT Connections Turns 1: These Are the 5 Toughest Puzzles So Far Hint for today's Strands puzzle Today's Strands theme is: Healthful helpers. If that doesn't help you, here's a clue: Morning meds, maybe. Clue words to unlock in-game hints Your goal is to find hidden words that fit the puzzle's theme. If you're stuck, find any words you can. Every time you find three words of four letters or more, Strands will reveal one of the theme words. These are the words I used to get those hints but any words of four or more letters that you find will work: TINE, BOOT, BOOTS, ROOT, ROOTS, POTS, POST, POOT, POOTS, STOP, TOPS, BOPS, PLUM, SEED, FLAX, TIDE. Answers for today's Strands puzzle These are the answers that tie into the theme. The goal of the puzzle is to find them all, including the spangram, a theme word that reaches from one side of the puzzle to the other. When you have all of them (I originally thought there were always eight but learned that the number can vary), every letter on the board will be used. Here are the nonspangram answers: ZINC, CALCIUM, FLAXSEED, MAGNESIUM, PROBIOTIC Today's Strands spangram The completed NYT Strands puzzle for June 24, 2025, #478. NYT/Screenshot by CNET Today's Strands spangram is SUPPLEMENTS. To find it, start with the S that's four letters to the right on the top row, and wind down.
